Once-weekly GLP-1RAs beneficial for type 2 diabetes

Once-weekly GLP-1RAs reduced HbA1c and fasting plasma glucose.
Once-weekly GLP-1RAs reduced HbA1c and fasting plasma glucose.

Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs), new therapeutic agents for the treatment of type 2 diabetes, have shown promise in the reduction of hemoglobin A1c (HbA1c) levels, fasting plasma glucose levels, and body weight, according to a systematic review and network meta-analysis published in the January 19 issue of the Annals of Internal Medicine. 


Senior author Melanie J. Davies, MD, and fellow investigators analyzed 34 randomized, controlled trials (21,126 participants; ≥24 weeks of follow-up) of albiglutide, dulaglutide, once-weekly exenatide, semaglutide, and taspoglutide. They found that all once-weekly GLP-1RAs reduced HbA1c and fasting plasma glucose, when compared with placebo. Compared with other once-weekly GLP-1RAs, dulaglutide (1.5 mg), once-weekly exenatide, and taspoglutide (20 mg) showed a greater reduction of HbA1c levels, fasting plasma glucose levels, and body weight. Taspoglutide, once-weekly exenatide, and dulaglutide reduced body weight, when compared with placebo. 


Among the drugs, differences found in blood pressure, blood lipid levels, and C-reactive protein levels were clinically insignificant. Once-weekly exenatide increased heart rate, compared with albiglutide and dulaglutide (1.4 to 3.2 beats/min). Taspoglutide had the highest risk for nausea. The risk for hypoglycemia among the once-weekly GLP-1RAs studied was similar. 


 

The study was limited by poor data on semaglutide, and the definitions of outcomes varied among the trials in the analysis, the authors said.


Loading links....
You must be a registered member of Clinical Advisor to post a comment.

Sign Up for Free e-newsletters